BENITIONSClinical Trial Intelligence

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Phase 2 Terminated NCT03346538

ConditionAcute Ischemic Stroke
PhasePhase 2
SponsorShionogi
StatusTerminated
Enrollment17 participants
InterventionsContinuous infusion high-dose MCI-186, Continuous infusion low-dose MCI-186, Continuous infusion placebo, Approved dosing regimen MCI-186, Approved dosing regimen placebo
Start dateNov 17, 2017
Completion dateMay 14, 2018
Results postedJan 9, 2025

Summary

To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.

Number of Participants With National Institutes of Health Stroke Scale (NIHSS) Score Improved.

Baseline up to Day 7 · Participants

Continuous Infusion High-dose Group (Group H)0 Participants
Continuous Infusion Low-dose Group (Group L)0 Participants
Approved Dosing Regimen Group (Control Group)0 Participants
Continuous Infusion High-dose Group (Group H)2 Participants
Continuous Infusion Low-dose Group (Group L)0 Participants
Approved Dosing Regimen Group (Control Group)1 Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.